Increased levels of anti-phosphatidylcholine and anti-phosphatidylethanolamine antibodies in pediatric patients with cerebral infarction.

Autor: Korematsu S; Department of Pediatrics, Oita University Faculty of Medicine, Hasama, Yufu, Oita 879-5593, Japan. Electronic address: kseigo@oita-u.ac.jp., Yamada H; Department of Pediatrics, Oita University Faculty of Medicine, Hasama, Yufu, Oita 879-5593, Japan., Miyahara H; Department of Pediatrics, Oita University Faculty of Medicine, Hasama, Yufu, Oita 879-5593, Japan., Ihara K; Department of Pediatrics, Oita University Faculty of Medicine, Hasama, Yufu, Oita 879-5593, Japan.
Jazyk: angličtina
Zdroj: Brain & development [Brain Dev] 2017 Jun; Vol. 39 (6), pp. 542-546. Date of Electronic Publication: 2017 Feb 24.
DOI: 10.1016/j.braindev.2017.01.010
Abstrakt: Cerebral infarction in children is rare and often occurs secondary to moyamoya disease, hereditary coagulopathies, vasculitis, antiphospholipid antibody syndrome, heart disease, mitochondrial disease. However, in some cases, the causes of cerebral infarction is unknown. In this study, we detected increased levels of serum anti-phosphatidylcholine and anti-phosphatidylethanolamine IgG antibodies in three pediatric patients with cerebral infarction whose primary disorders are unknown by routine examination. For the five disease control patients of cerebral infarction due to other primary disorders, there was no such increase in these antibodies levels. Phosphatidylcholine and phosphatidylethanolamine are major components of the phospholipids of vascular endothelial cells, while cardiolipin is a minor component. Anti-phosphatidylcholine and anti-phosphatidylethanolamine antibodies, as well as anti-cardiolipin antibody, might also be risk factors with cerebral infarction.
(Copyright © 2017 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: